ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 2326

Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis

Michael Dreyfuss1, Dan Riesel2, Guy Shalev2, Benjamin Getz3, Or Ramni2, Yonatan Jenudi4, Dimid Duchovny2, Daniel Underberger5, Shlomit Steinberg-Koch2, Douglas White6 and Elena Myasoedova7, 1Predicta Med, Ramat Gan, Israel, 2Predicta Med Analytics Ltd., Ramat Gan, Israel, 3CTO, Ramat Gan, Israel, 4[email protected], Ramat Gan, Israel, 5Predicta Med Analytics Ltd., Bridgeport, CT, 6Gundersen Health System, Onalaska, WI, 7Mayo Clinic, Rochester, MN

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Bioinformatics, primary care, Psoriatic arthritis, risk assessment

Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Delays in diagnosis of psoriatic arthritis (PsA) are associated with indolent and non-specific signs and symptoms, and often result in physical impairment and poorer global health outcomes in the long term [1,2,3,4]. Digital tools such as machine learning algorithms have the potential to address diagnostic delays by identifying patients earlier in their disease course [5]. The purpose of this study was to develop and evaluate a novel machine learning model for identifying patients at risk of having undiagnosed PsA among patients who saw primary care services at Mayo Clinic.

Methods: Patients receiving primary care services (n=395,918 patients) at Mayo Clinic between 2012 and 2022 were split into training and testing sets. Cases with incident PsA (n=326) and controls with no evidence of PsA (n=395,592) were identified in both sets. For model training, each patient was assigned a prediction date, which preceded the initial diagnosis of PsA for cases, and was randomly assigned to controls. A gradient boosted trees algorithm was trained using electronic medical record (EMR) data documented during the two years prior to each patient’s prediction date. Input features included age, sex, diagnosis codes, medication prescriptions and laboratory results. The model was then evaluated in the test set on predictions made on 1 January 2018 with input data from the preceding two years. Area under the curve (AUC) was used to assess the model’s ability to discriminate between new cases of PsA diagnosed during and after 2018 and controls.

Results:  The testing set included 89 patients with PsA (60 female; mean age 54.2, standard deviation [SD] 14.0) and 284,480 control patients (167,018 females; mean age 51.9, SD 18.2). The AUC on the test was 79.6% (fig 1). The top predictive features preceding the initial PsA diagnosis include diagnoses of psoriasis, joint pain and tenosynovitis, glucocorticoid and NSAID use, high body mass index, elevated CRP, ALT, triglycerides and decreased HDL (fig 2).

Conclusion: The model displayed good performance in its ability to discriminate between cases of PsA and controls. The model selected input features associated with preexisting psoriasis, joint inflammation and an adverse metabolic profile [6]. Implementation of the model may help identify patients with undiagnosed PsA in the primary care population using EMR. Improving time to diagnosis could help patients receive treatment and reduce downstream sequelae from untreated disease.

Supporting image 1

Receiver operating characteristics curve displaying the discriminative ability of the model over all thresholds.

Supporting image 2

SHAP plot indicating the top features contributing to model classification output. Features that are derived from diagnosis codes (‘dx’), lab results, prescriptions are indicated. Female is coded as 1 for gender.


Disclosures: M. Dreyfuss: Predicta Med Analytics Ltd., 3, 8; D. Riesel: Predicta Med Analytics Ltd., 1, 3, 8, 8; G. Shalev: Predicta Med Analytics Ltd., 3, 8; B. Getz: Predicta Med Analytics Ltd., 3, 8; O. Ramni: Predicta Med Analytics Ltd., 3, 8; Y. Jenudi: Predicta Med Analytics Ltd., 3, 8; D. Duchovny: Predicta Med Analytics Ltd., 3, 8; D. Underberger: Predicta Med Analytics Ltd., 3, 8; S. Steinberg-Koch: Predicta Med Analytics Ltd., 3, 8; D. White: Predicta Med Analytics Ltd., 1, 8; E. Myasoedova: None.

To cite this abstract in AMA style:

Dreyfuss M, Riesel D, Shalev G, Getz B, Ramni O, Jenudi Y, Duchovny D, Underberger D, Steinberg-Koch S, White D, Myasoedova E. Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/development-and-evaluation-of-a-machine-learning-model-for-the-early-identification-of-psoriatic-arthritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-and-evaluation-of-a-machine-learning-model-for-the-early-identification-of-psoriatic-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology